Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer.

The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.

Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers.

The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810.

Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs.

Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019.

The company was incorporated in 2015 and is based in Foster City, California.